Fentanyl
- Generic Name
- Fentanyl
- Brand Names
- Abstral, Actiq, Duragesic, Effentora, Fentora, Instanyl, Lazanda, Sublimaze, Subsys, PecFent
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N2O
- CAS Number
- 437-38-7
- Unique Ingredient Identifier
- UF599785JZ
- Background
Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia. Fentanyl is related to other opioids like morphine and oxycodone.
Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily.
Fentanyl was FDA approved in 1968.
- Indication
Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia. These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia. Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.
Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.
- Associated Conditions
- Cancer Related Pain (Breakthrough Pain), Severe, Chronic Pain
- Associated Therapies
- Anesthetic premedication therapy, Anesthetics Agent, General Anesthesia, Induction of anesthesia therapy, Maintenance of anesthesia therapy, Regional Anesthesia therapy
Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse
- First Posted Date
- 2011-03-10
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Hurd,Yasmin, Ph.D.
- Target Recruit Count
- 18
- Registration Number
- NCT01311778
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
Sedation in Endoscopic Retrograde Cholangiopancreatography (ERCP) With or Without Opioids
- Conditions
- Chronic Pain
- Interventions
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2013-08-05
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 180
- Registration Number
- NCT01304342
- Locations
- 🇬🇷
Department of Anesthesiology, Aretaieio Hospital, Athens, Greece
Airway Responses During Desflurane Anesthesia Via a Laryngeal Mask Airway: Effects of Fentanyl Pretreatment
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT01277861
- Locations
- 🇺🇸
Ut Southwestern Medical Center At Dallas, Dallas, Texas, United States
Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 60
- Registration Number
- NCT01270659
- Locations
- 🇺🇸
Hillcrest Medical Center Emergency Department, Tulsa, Oklahoma, United States
Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction
- Conditions
- Postoperative Pain After Breast Reconstruction With Abdominal Flap
- Interventions
- Drug: Inactive patchDrug: Fentanyl
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 60
- Registration Number
- NCT01258296
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Nasal Fentanyl for Patient Controlled Treatment of Pain in Cancer
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- St. Olavs Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT01248611
- Locations
- 🇳🇴
St.Olavs University Hospital, Trondheim, Norway
Pain, Opioids and Pro-Inflammatory Immune Responses
- Conditions
- Pro-inflammatory ActivityImmunologic Activity Alteration
- Interventions
- First Posted Date
- 2010-09-28
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 21
- Registration Number
- NCT01210066
- Locations
- 🇺🇸
UCLA School of Nursing, Los Angeles, California, United States
Comparison of Postoperative Analgesic Effect of Intrathecal Magnesium and Fentanyl Added to Bupivacaine in Patients Undergoing Lower Limb Orthopedic Surgery
- Conditions
- Post Operative Pain
- Interventions
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Qazvin University Of Medical Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT01205997
- Locations
- 🇮🇷
Qazvin university of medical science, Qazvin, Iran, Islamic Republic of
Comparison of Different Doses of Clonidine to Fentanyl as an Adjuvant to Bupivacaine 0.5% for Spinal Anesthesia
- Conditions
- Undergoing Lower Segment Caesarian SectionFull Term Pregnant Patients
- Interventions
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Pravara Institute of Medical Sciences University
- Registration Number
- NCT01205204
Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery
- Conditions
- Regional Anesthesia BlockOrthopedic SurgeryProcedural Sedation
- Interventions
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2012-06-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 13
- Registration Number
- NCT01195103
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.